Announced Date: 2022-04-01 (April 01, 2024)
Asset: GFH009
Licensor: GenFleet Therapeutics (China)
Licensee (Buyer): SELLAS Life Sciences Group (US)
.
Asset Modality: Small molecule, orally
Asset Target: Cyclin-dependent kinase 9 (“CDK9”) inhibitor,
Potential Indication: Cancer
Current Stage: Phase 1 clinical trials in the United States and China
.
Scope of Authority:
GenFleet grants rights to SELLAS for the development and commercialization of GFH009 across all therapeutic and diagnostic uses worldwide outside of Greater China (the Chinese mainland, Hong Kong, Macau and Taiwan).
.
Payment Detail:
SELLAS will pay to GenFleet
(i) an initial payment of $10 million as an upfront license and technology transfer fee, a portion of which is payable within 30 days of the execution of the license agreement with the remainder due upon the completion of the technology transfer,
(ii) development and regulatory milestone payments for up to three indications totaling up to $48 million in the aggregate,
(iii) milestone payments totaling up to $92 million in the aggregate upon the achievement of certain net sales thresholds of GFH009 in the United States and rest of the world other than Greater China in a given calendar year.
SELLAS will also pay GenFleet tiered royalties based on a percentage of annual net sales of GFH009 ranging from the low to high single digits.
.
Link:
GenFleet and SELLAS Announce Global License Agreement-GenFleet Therapeutics
